vs
Ranpak Holdings Corp.（PACK）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Ranpak Holdings Corp.的1.4倍（$127.1M vs $93.7M），再鼎医药同比增速更快（17.1% vs 2.3%），过去两年再鼎医药的营收复合增速更高（20.8% vs 13.7%）
Ranpak Holdings Corp.主营生产防护纸质包装设备与纸制品，可为电商及各行业货品运输提供纸质缓冲包装方案，同时也供应自动化包装解决方案。公司总部位于美国俄亥俄州康科德，在美国本土多个州、捷克、荷兰、中国上海及新加坡均设有生产基地与办公室，产品可用于包裹缠绕、缓冲填隙、冷链运输等多种场景。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PACK vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$93.7M
营收增速更快
ZLAB
高出14.8%
2.3%
两年增速更快
ZLAB
近两年复合增速
13.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $93.7M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 39.0% | 51.0% |
| 营业利润率 | -1.0% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 2.3% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PACKZLAB
| Q4 25 | $93.7M | $127.1M | ||
| Q3 25 | $83.6M | $115.4M | ||
| Q2 25 | $77.8M | $109.1M | ||
| Q1 25 | $77.6M | $105.7M | ||
| Q4 24 | $91.6M | $108.5M | ||
| Q3 24 | $78.6M | $101.8M | ||
| Q2 24 | $72.8M | $100.1M | ||
| Q1 24 | $72.5M | $87.1M |
净利润PACKZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-10.4M | $-36.0M | ||
| Q2 25 | $-7.5M | $-40.7M | ||
| Q1 25 | $-10.9M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.1M | $-41.7M | ||
| Q2 24 | $5.5M | $-80.3M | ||
| Q1 24 | $-8.1M | $-53.5M |
毛利率PACKZLAB
| Q4 25 | 39.0% | 51.0% | ||
| Q3 25 | 41.1% | 59.5% | ||
| Q2 25 | 37.1% | 60.6% | ||
| Q1 25 | 39.8% | 63.6% | ||
| Q4 24 | 45.2% | 61.5% | ||
| Q3 24 | 43.8% | 64.1% | ||
| Q2 24 | 43.5% | 64.9% | ||
| Q1 24 | 44.6% | 61.4% |
营业利润率PACKZLAB
| Q4 25 | -1.0% | -54.6% | ||
| Q3 25 | -6.8% | -42.3% | ||
| Q2 25 | -12.5% | -50.3% | ||
| Q1 25 | -10.3% | -53.3% | ||
| Q4 24 | 1.5% | -62.6% | ||
| Q3 24 | -5.3% | -66.6% | ||
| Q2 24 | -7.1% | -76.0% | ||
| Q1 24 | -6.6% | -80.7% |
净利率PACKZLAB
| Q4 25 | — | — | ||
| Q3 25 | -12.4% | -31.2% | ||
| Q2 25 | -9.6% | -37.3% | ||
| Q1 25 | -14.0% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -10.3% | -40.9% | ||
| Q2 24 | 7.6% | -80.2% | ||
| Q1 24 | -11.2% | -61.4% |
每股收益（稀释后）PACKZLAB
| Q4 25 | $-0.11 | $-0.05 | ||
| Q3 25 | $-0.12 | $-0.03 | ||
| Q2 25 | $-0.09 | $-0.04 | ||
| Q1 25 | $-0.13 | $-0.04 | ||
| Q4 24 | $-0.13 | $-0.09 | ||
| Q3 24 | $-0.10 | $-0.04 | ||
| Q2 24 | $0.07 | $-0.08 | ||
| Q1 24 | $-0.10 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.0M | $689.6M |
| 总债务越低越好 | $401.9M | — |
| 股东权益账面价值 | $534.9M | $715.5M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.75× | — |
8季度趋势，按日历期对齐
现金及短期投资PACKZLAB
| Q4 25 | $63.0M | $689.6M | ||
| Q3 25 | $49.9M | $717.2M | ||
| Q2 25 | $49.2M | $732.2M | ||
| Q1 25 | $65.5M | $757.3M | ||
| Q4 24 | $76.1M | $779.7M | ||
| Q3 24 | $69.5M | $616.1M | ||
| Q2 24 | $65.1M | $630.0M | ||
| Q1 24 | $55.1M | $650.8M |
总债务PACKZLAB
| Q4 25 | $401.9M | — | ||
| Q3 25 | $403.1M | — | ||
| Q2 25 | $403.1M | — | ||
| Q1 25 | $405.2M | — | ||
| Q4 24 | $406.4M | — | ||
| Q3 24 | $403.2M | — | ||
| Q2 24 | $396.1M | — | ||
| Q1 24 | $396.7M | — |
股东权益PACKZLAB
| Q4 25 | $534.9M | $715.5M | ||
| Q3 25 | $537.8M | $759.9M | ||
| Q2 25 | $539.0M | $791.7M | ||
| Q1 25 | $544.1M | $810.8M | ||
| Q4 24 | $548.1M | $840.9M | ||
| Q3 24 | $564.3M | $667.7M | ||
| Q2 24 | $566.2M | $704.2M | ||
| Q1 24 | $560.0M | $762.2M |
总资产PACKZLAB
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.1B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
负债/权益比PACKZLAB
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.75× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PACKZLAB
| Q4 25 | $19.5M | $-26.0M | ||
| Q3 25 | $8.5M | $-32.0M | ||
| Q2 25 | $-3.6M | $-31.0M | ||
| Q1 25 | $-1.3M | $-61.7M | ||
| Q4 24 | $6.5M | $-55.8M | ||
| Q3 24 | $10.1M | $-26.8M | ||
| Q2 24 | $19.6M | $-42.2M | ||
| Q1 24 | $5.2M | $-90.1M |
自由现金流PACKZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率PACKZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度PACKZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率PACKZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.56× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
